Takeda receives Japanese approval for subcutaneous Entyvio® (vedolizumab)

Takeda Pharmaceuticals announced that it received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market its subcutaneous (SC) formulation of vedolizumab, Entyvio®.  The approval covers both pens and syringes for SC injection.  The SC products were approved as maintenance therapy for moderate to severe ulcerative colitis in patients with inadequate response to conventional treatment.